Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company had vide its letter dated 23rd June, 2023, intimated about US FDA inspection of Company’s formulations manufacturing facility situated at SEZ Indore, Pithampur (Madhya Pradesh) from 15th June, 2023 to 23rd June, 2023. Ipca Laboratories has informed that this manufacturing facility has now received Establishment Inspection Report classifying the manufacturing facility as ‘Voluntary Action Indicated (VAI) and that that this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).
The above information is a part of company’s filings submitted to BSE.
